Literature DB >> 17194761

Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Eduard Bitto1, Craig A Bingman, Gary E Wesenberg, Jason G McCoy, George N Phillips.   

Abstract

Aspartoacylase catalyzes hydrolysis of N-acetyl-l-aspartate to aspartate and acetate in the vertebrate brain. Deficiency in this activity leads to spongiform degeneration of the white matter of the brain and is the established cause of Canavan disease, a fatal progressive leukodystrophy affecting young children. We present crystal structures of recombinant human and rat aspartoacylase refined to 2.8- and 1.8-A resolution, respectively. The structures revealed that the N-terminal domain of aspartoacylase adopts a protein fold similar to that of zinc-dependent hydrolases related to carboxypeptidases A. The catalytic site of aspartoacylase shows close structural similarity to those of carboxypeptidases despite only 10-13% sequence identity between these proteins. About 100 C-terminal residues of aspartoacylase form a globular domain with a two-stranded beta-sheet linker that wraps around the N-terminal domain. The long channel leading to the active site is formed by the interface of the N- and C-terminal domains. The C-terminal domain is positioned in a way that prevents productive binding of polypeptides in the active site. The structures revealed that residues 158-164 may undergo a conformational change that results in opening and partial closing of the channel entrance. We hypothesize that the catalytic mechanism of aspartoacylase is closely analogous to that of carboxypeptidases. We identify residues involved in zinc coordination, and propose which residues may be involved in substrate binding and catalysis. The structures also provide a structural framework necessary for understanding the deleterious effects of many missense mutations of human aspartoacylase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194761      PMCID: PMC1766406          DOI: 10.1073/pnas.0607817104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  64 in total

Review 1.  Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice.

Authors:  M H Baslow
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay.

Authors:  Annette Feigenbaum; Robert Moore; Joe Clarke; Stacy Hewson; David Chitayat; Peter N Ray; Tracy L Stockley
Journal:  Am J Med Genet A       Date:  2004-01-15       Impact factor: 2.802

3.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.

Authors:  R Kaul; G P Gao; R Matalon; M Aloya; Q Su; M Jin; A B Johnson; R B Schutgens; J T Clarke
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

4.  Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.

Authors:  K Kitada; T Akimitsu; Y Shigematsu; A Kondo; T Maihara; N Yokoi; T Kuramoto; M Sasa; T Serikawa
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

5.  Threading a database of protein cores.

Authors:  T Madej; J F Gibrat; S H Bryant
Journal:  Proteins       Date:  1995-11

6.  N-acetylaspartate as a reservoir for glutamate.

Authors:  Joseph F Clark; Amos Doepke; Jessica A Filosa; Robert L Wardle; Aigang Lu; Timothy J Meeker; Gail J Pyne-Geithman
Journal:  Med Hypotheses       Date:  2006-05-26       Impact factor: 1.538

Review 7.  Principles of protein-protein interactions.

Authors:  S Jones; J M Thornton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.

Authors:  R Kaul; G P Gao; K Balamurugan; R Matalon
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

9.  Immunohistochemical localization of aspartoacylase in the rat central nervous system.

Authors:  Chikkathur N Madhavarao; John R Moffett; Roger A Moore; Ronald E Viola; M A Aryan Namboodiri; David M Jacobowitz
Journal:  J Comp Neurol       Date:  2004-05-03       Impact factor: 3.215

10.  The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients.

Authors:  A Shaag; Y Anikster; E Christensen; J Z Glustein; A Fois; H Michelakakis; F Nigro; E Pronicka; A Ribes; M T Zabot
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

View more
  26 in total

1.  Structures of aminoacylase 3 in complex with acetylated substrates.

Authors:  Jennifer M Hsieh; Kirill Tsirulnikov; Michael R Sawaya; Nathaniel Magilnick; Natalia Abuladze; Ira Kurtz; Jeff Abramson; Alexander Pushkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Expression and localization of myosin-1d in the developing nervous system.

Authors:  Andrew E Benesh; Jonathan T Fleming; Chin Chiang; Bruce D Carter; Matthew J Tyska
Journal:  Brain Res       Date:  2012-01-08       Impact factor: 3.252

3.  The impact of structural biology on neurobiology.

Authors:  Ronald E Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

4.  Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.

Authors:  Stephen Zano; Radhika Malik; Sylvia Szucs; Reuben Matalon; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2010-10-30       Impact factor: 4.797

Review 5.  Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.

Authors:  George N Phillips; Brian G Fox; John L Markley; Brian F Volkman; Euiyoung Bae; Eduard Bitto; Craig A Bingman; Ronnie O Frederick; Jason G McCoy; Betsy L Lytle; Brad S Pierce; Jikui Song; Simon N Twigger
Journal:  J Struct Funct Genomics       Date:  2007-09-06

6.  Stimulation-induced transient changes in neuronal activity, blood flow and N-acetylaspartate content in rat prefrontal cortex: a chemogenetic fMRS-BOLD study.

Authors:  Morris H Baslow; Christopher K Cain; Robert Sears; Donald A Wilson; Alvin Bachman; Scott Gerum; David N Guilfoyle
Journal:  NMR Biomed       Date:  2016-10-03       Impact factor: 4.044

7.  Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae).

Authors:  Richard E Connon; Juergen Geist; Janice Pfeiff; Alexander V Loguinov; Leandro S D'Abronzo; Henri Wintz; Christopher D Vulpe; Inge Werner
Journal:  BMC Genomics       Date:  2009-12-15       Impact factor: 3.969

8.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

9.  Novel mutation in an Egyptian patient with infantile Canavan disease.

Authors:  Osama K Zaki; Heba S El Abd; Shaimaa A Mohamed; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2015-11-28       Impact factor: 3.584

10.  Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.

Authors:  Johanne Le Coq; Alexander Pavlovsky; Radhika Malik; Ruslan Sanishvili; Chengfu Xu; Ronald E Viola
Journal:  Biochemistry       Date:  2008-02-23       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.